Objective: Choice of hysterectomy and adjuvant treatment for International Federation of Gynecology and Obstetrics (FIGO) 2009 stage II endometrioid endometrial cancer (EEC) is still controversial. Aims of this study were to evaluate survival benefits and adverse effects of different hysterectomies with or without adjuvant radiotherapy (RT), and to identify prognostic factors. Methods: The patients at 14 member hospitals of the Taiwanese Gynecologic Oncology Group from 1992 to 2013 were retrospectively investigated. Patients were divided into simple hysterectomy (SH) alone, SH with RT, radical hysterectomy (RH) alone, and RH with RT groups. Endpoints were recurrence-free survival (RFS), overall survival (OS), disease-specific survival (DSS), adverse effects and prognostic factors for survival. Results: Total of 246 patients were enrolled. The 5-year RFS, OS, DSS and recurrence rates for the entire cohort were 89.5%, 94.3%, 96.2% and 10.2%, respectively. Patients receiving RH had more adverse effects including blood loss (p<0.001), recurrent urinary tract infections (p=0.013), and leg lymphedema (p=0.038). Age over 50-year (HR=9.2; 95% confidence
INTRODUCTION
Endometrial cancer (EC) is one of the most common gynecologic cancers worldwide [1] . In Taiwan, the incidence of EC has increased rapidly in the past decade [2] . The most common histology is the endometrioid type, and the majority of tumors are confined to the uterine corpus. The 2009 International Federation of Gynecology and Obstetrics (FIGO) staging defined stage II disease as pathologic involvement of the uterine cervix stroma [3] . The presence of glandular involvement was not included in the definition of stage II disease because the prognosis of these patients was not worse than those with stage I. According to previous reports, 7%-12% of ECs are stage II [4] [5] [6] .
Total hysterectomy, bilateral salpingo-oophorectomy (BSO), and bilateral pelvic and paraaortic lymph node dissection are recommended as staging surgery for EC [7] . The optimal type of hysterectomy for patients with stage II EC remains controversial, and treatment options range from simple (extrafascial) hysterectomy (SH) to radical hysterectomy (RH). RH has been recommended for stage II disease due to improvements in locoregional control and survival compared with SH [8, 9] . However, other studies that evaluated the prognostic factors in patients with FIGO 2009 stage II did not find that the type of hysterectomy was a risk factor for survival or recurrence [10] [11] [12] [13] [14] . Therefore, the choice of hysterectomy for stage II EC is still controversial. Thus, we conducted a retrospective, multicenter study to evaluate survival benefits and adverse effects of different hysterectomies with or without adjuvant RT, and to identify prognostic factors among patients with FIGO stage II endometrioid endometrial cancer (EEC).
MATERIALS AND METHODS

Patients
The medical records of patients who underwent primary treatment between January 1992 and December 2013 at the member hospitals of the Taiwanese Gynecologic Oncology Group (TGOG) were retrospectively reviewed. The study protocol was approved by the Institutional Review Board of each hospital (approval number: 105-3816C). The inclusion criterion was post-operative pathology-proven FIGO 2009 stage II EEC. Patients with incomplete surgical staging (without BSO or lymphadenectomy), an inaccurate pathology report, incomplete medical records, or a lack of follow-up were excluded from the study. The detailed medical records were retrospectively evaluated until the end of the follow-up period (31 December 2014). 
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Demographic data, including age at the time of surgery, body mass index (BMI), parity, menopausal status, and history of medical diseases were obtained from the medical records. The staging and histologic grading criteria were determined post-operatively and were based on the FIGO 2009 staging system [3] . Surgical staging procedures consisted of washing cytology, SH or RH, BSO, and lymph node dissection (pelvic with or without para-aortic). The decision to give the patients adjuvant therapy was based on the extent of the disease, medical co-morbidities, and the institutional practices during that time. 
Statistical methods
Recurrence-free survival (RFS) and locoregional recurrence free survival (LRFS) was calculated from the date of staging surgery to the date of diagnosis of recurrence or last contact for the recurrence-free patients. Locoregional recurrence was defined as the vaginal stump, pelvic or vaginal with pelvic recurrence. Overall survival (OS) was defined as the period from the date of surgery to the date of death or last contact. Disease-specific survival (DSS) was defined as the date of surgery to the date of death from EC or last contact.
The χ 2 test was used to analyze categorical variables and the Student's t-test was used for continuous variables. The Kaplan-Meier method was used to calculate patient survival distribution. The significance of the survival distribution in each group was tested using the log-rank test. Cox proportional hazard analysis was used to evaluate the prognostic factors for survival. Multivariate analysis using Cox stepwise forward regression was conducted for the covariates in univariate analysis with a p-value <0.05, hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated. A p-value <0.05 was considered to be statistically significant. All statistical calculations were performed using SPSS software for Windows version 20 (SPSS Inc., Chicago, IL, USA).
RESULTS
Characteristics of the patients
We identified 246 patients with stage II (FIGO 2009) EEC who were treated between 1992 and 2013 at the 14 TGOG member hospitals (Fig. 1) . The median duration of follow-up was 78 months (range, 0.5-259 months). 
Survival pattern of the patients receiving different treatments
The 5-year RFS, OS, DSS, and LRFS, for the entire cohort were 89.5%, 94.3%, 96.2%, and 93.8%, respectively. RFS, LRFS, OS, and DSS curves of the patients receiving different treatment modalities are shown in Fig. 2 , respectively. There were also no significant survival differences among the different treatment modalities.
Pattern of recurrence according to treatment
Twenty-five (10.2%) patients were diagnosed with tumor recurrences. There was a significant difference in the site of recurrence between the 4 groups (p=0.046; Table 2 ). The patients who received adjuvant RT had a lower locoregional recurrence rate (3.0% vs. 10.0%, p=0.021) regardless of the type of hysterectomy. 
Acute and chronic adverse effects according to different treatments
Adverse effects according to the treatment modality are shown in Table 3 . The patients who received RH had significantly longer operative time and hospital stay, and more surgical blood loss. Of the chronic adverse effects, vesicovaginal fistulas and recurrent urinary tract infections were more frequently observed in the RH with or without RT groups (p=0.013). The patients who received SH only had the lowest rate of lower limb lymphedema (p=0.038). Lower limb lymphedema was most frequently observed in the RH with RT group.
Analysis of risk factors for recurrence and patient survival
The results of univariate (log-rank test) and multivariate (Cox proportional hazard) analyses of RFS, OS, DSS, and LRFS, are shown in Supplementary Tables 5-8 , respectively. Based on the multivariate analysis ( 
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DISCUSSION
This study demonstrated that the type of surgery was not associated with RFS, DSS, or OS for patients with FIGO 2009 stage II EEC regardless of whether or not they received RT. Adjuvant RT significantly improved the locoregional control rate, but not survivals. High tumor grade was an independent predictor of RFS, OS, DSS and LRFS. Age (≥50-years) was also an independent predictor of OS ( Table 4) .
In our series, the 5-year RFS, OS, and DSS rates for all of the patients were 89.5%, 94.3%, and 96.2%, respectively. The survival rates were better than previous reports [10] [11] [12] [13] 16, 17] . A possible explanation for this finding is that we only included patients with FIGO 2009 stage II EEC with complete staging surgery; patients with high-risk histologic subtypes (carcinosarcoma, serous and clear cell carcinoma) were excluded from this study. Another interesting finding is that our patients were much younger than previously reported [7] . Age is known as a risk factor for survival [11, 12, 16] , and the median age at diagnosis was 52 years (range, 26-86 years) in this study. This is not due to patient selection bias, because in Taiwan the median age at the time of diagnosis of uterine corpus cancer is 55 years [24] , which is also younger than in a previous report [7] . In Mahdi et al.'s study [17] , Asian women are younger than non-Hispanic white women at the initial presentation of endometrial adenocarcinoma. Further studies are required to investigate possible explanations for such racial differences.
Cohn et al. [18] and Sartori et al. [19] reported statistically significant improvements in 5-year survival in patients who underwent RHs; however, their results were not based on multivariate analysis. In addition, not all of the patients in the reports received adequate lymphadenectomies. Because cervical involvement is a risk factor for lymph node metastasis [20] [21] [22] , these patients may have been assigned to a higher stage due to lymph node metastasis. In contrast, other investigators have not reported a survival benefit based on the type of surgical procedure performed [11, 12, 14, 16] . In our multivariate model, RH had no significant beneficial effect on OS, RFS, DSS, or LRFS. RH alone does not increase survival in stage II EC, as in cervical cancer, because the tumor behavior is different for EC with cervical involvement compared to primary cervical cancer. A lower parametrium invasion [23] and higher pelvic lymph node metastasis had been reported in patients with EC with cervical involvement [20] . RH is mostly beneficial in women with gross cervical involvement preoperatively [16] .
After surgery for EC, external beam or vaginal brachytherapy is recommended for women with stage II disease [8] . A systematic review and meta-analysis assessed the benefits of adjuvant RT in women with early EC [25, 26] . The investigators found that adjuvant RT reduced the risk of locoregional recurrence, but did not impact DSS or OS [13, 16, 19, 25, 26] . In our study, we also found that adjuvant RT improved locoregional control, but did no impact on RFS, OS, or DSS. Even, the patients with adjuvant RT had poor histologic factors as deeper myometrium invasion and LVSI (Supplementary Table 2 ).
There were no significant differences in major acute side effects including major organ injuries or death between the SH and RH groups in this study. RH required a significantly longer operative time, was associated with greater intra-operative blood loss, and led to longer hospital stay. Chronic side effects, including recurrent urinary tract infections, and leg edema occurred more frequently in the RH group. Our patients receiving RH and adjuvant RT had the highest rate of grade 3 leg edema (11.5%). Other investigators had reported that complications occurred more frequently in RH patients [10, 11] .
In the present study, histologic grade was an independent prognostic factor for OS, RFS, DSS, and locoregional recurrence (Supplementary Fig. 1) , which is consistent with previous studies [9, 12, 13, 16, 27] . Both locoregional and distant recurrence rate were much higher in the patients with G3 tumors than in those with G1/G2 tumors (p=0.007, Supplementary Table  9 ). This finding suggests that adjuvant CT may play a role in these patients. Susumu et al. [28] reported a randomized control trial that compared pelvic RT and CT with cyclophosphamide, doxorubicin, and cisplatin in patients with stage IC-IIIC EC, and suggested a survival advantage with CT in the patients from the high-to-intermediate risk group ( [9, 11, 12, 16, 23] . This is also the largest series to date on women with FIGO 2009 stage II EEC with complete staging surgery.
The limitations of this study included the retrospective design and lack of central pathologic review. The retrospective nature of the current study and the potential for selection bias is the main limitation. We included patients who were treated over a long period of time (>20 years), and developments in RT technology were not considered in this study. In addition, the patients were treated at different academic institutions with different philosophies with regards to surgery and adjuvant treatments.
In conclusion, we demonstrated that different treatment modalities for FIGO stage II disease yielded similar survival outcomes. Adjuvant RT reduced locoregional recurrence, but did not have any impact on survival. If gross cervical involvement was found pre-operatively, RH may be beneficial. For small or subtle cervical lesions of patients with EC found by pelvic examination or imaging study before surgery, SH with RT appeared to be a suitable treatment strategy for FIGO 2009 stage II EEC due to acceptable morbidity and lower locoregional recurrence. Patients with poor prognostic factors including older age and high histologic grade (G3) may need aggressive adjuvant therapy such as RT or CT. Further well-designed studies are required to confirm our findings.
